SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

▤ Summary

SOPHiA GENETICS has signed an MOU with Memorial Sloan Kettering Cancer Center to explore a joint venture focused on precision oncology. The proposed hub would combine MSK’s clinical data and oncology expertise with SOPHiA GENETICS’s AI and analytics platform. The collaboration aims to speed up the development and deployment of multimodal precision medicine capabilities for patients worldwide. It could also create an infrastructure opportunity for biopharma partners that need companion diagnostics, clinical algorithms, and evidence generation support.

▦ Linked Companies

SOPHiA GENETICS

$50M to $100M